November 22, 2016

<Recipent>

Re: Cigna Integrated Oncology Management Program

Dear <Recipent>,

We are committed to creating programs that help ensure our customers receive coverage for high quality, medically appropriate care that is consistent with evidence-based treatment guidelines. As part of these efforts, we will implement an Integrated Oncology Management Program for cancer treatment plans, beginning February 20, 2017.

As part of this program, we will partner with eviCore healthcare to provide utilization management – including precertification – for medical and pharmacy oncology medications that currently require precertification through Cigna.

What this means to you

Beginning February 20, 2017, you must request precertification for affected medical oncology medications, which include primary chemotherapy and supportive drugs (e.g., medical injectables and infusions) through eviCore instead of Cigna.* eviCore will review your patient’s entire treatment plan – rather than each medication individually – for consistency with National Comprehensive Cancer Network (NCCN)® practice guidelines in oncology and our medical oncology coverage policies. Effective July 1, 2017, we will expand the program to include precertification for oral chemotherapy medications using the same NCCN guidelines.

Our Integrated Oncology Management Program will allow you to obtain precertification for covered medical and pharmacy medications with a single request, resulting in a streamlined, integrated approach to cancer treatment. With this approach, we will help you to provide your patients a coordinated, medically appropriate course of treatment.

Please note that for your patients who are undergoing active approved treatments on and after February 20, 2017, their existing medical and pharmacy authorizations will continue as previously approved.

How to request precertification for medical oncology medications beginning February 20, 2017

The preferred and most efficient method for requesting precertification is through eviCore’s website at https://www.evicore.com/pages/providerlogin.aspx. If you are not registered for this website, click Register to get started.

While submitting requests through the website is highly encouraged, providers can also request precertification through our dedicated telephone number: 1.866.668.9250 (7:00 am – 7:00 pm EST).

Additional details about the affected medications

- A list of medical oncology medications requiring precertification is available at https://www.evicore.com/Cigna/Pages/MedicalOncology.aspx.
- Additional information about our coverage guidelines can be found at https://www.evicore.com/resources/pages/providers.aspx.

(over)
Site of care
To help ensure consistency with the patient’s benefit plan, we may review the medical necessity for the site of care for Neulasta, Sandostatin, and Lanreotide during the precertification process when these drugs are proposed to be administered in an outpatient hospital setting. If clinically appropriate, we will help facilitate the administration of the drug at a less intense site of care such as a non-hospital-affiliated provider’s office, a freestanding infusion center, or the patient’s home.

Why eviCore
For more than two decades, eviCore has built industry-leading, innovative benefit management programs on the foundation of helping providers deliver better quality health care, while lowering health care costs for customers. eviCore engages board-certified physicians in medical oncology to help ensure that patients receive coverage for tests and treatments that improve their conditions and follow established evidence-based coverage guidelines. Ultimately, this helps ensure affordability for our customers and clients, while maintaining high quality care for your patients.

What happens next
Beginning in January 2017, eviCore will be leading online orientation sessions designed to assist you and your staff with our new Integrated Oncology Management Program. These sessions will include detailed information about the precertification process, accessing information from the eviCore website, and a question-and-answer session.

eviCore will send you a letter in January that will provide additional details and registration instructions for these training sessions. We encourage you and your staff to attend one of these informative sessions to ensure your understanding of the new precertification process for the Integrated Oncology Management Program.

Additional information
For additional information about this program, please refer to the enclosed quick reference guide. You can also visit our dedicated program website at https://www.evicore.com/Cigna/Pages/MedicalOncology.aspx for additional resources, including frequently asked questions.

If you do not have Internet access or would like additional information about this program, please call Cigna Customer Service at 1.800.88Cigna (882.4462).

Thank you for the care you provide our customers.

Sincerely,

Dr. Ajani Nimmagadda
Senior Medical Director

Enclosure